Literature DB >> 30630101

Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win.

Frank I Scott1, Siddharth Singh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30630101      PMCID： PMC6612465          DOI： 10.1016/j.cgh.2018.12.047

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  20 in total

1.  Comparing approaches to causal inference for longitudinal data: inverse probability weighting versus propensity scores.

Authors:  Ashkan Ertefaie; David A Stephens
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

2.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.

Authors:  Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-05       Impact factor: 2.890

3.  Efficacy vs effectiveness.

Authors:  Sherry L Pagoto; Stephenie C Lemon
Journal:  JAMA Intern Med       Date:  2013-07-08       Impact factor: 21.873

4.  American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

Authors:  Jonathan P Terdiman; Claudia B Gruss; Joel J Heidelbaugh; Shahnaz Sultan; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2013-12       Impact factor: 22.682

Review 5.  Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

Authors:  Parambir S Dulai; Corey A Siegel; Jean-Frederic Colombel; William J Sandborn; Laurent Peyrin-Biroulet
Journal:  Gut       Date:  2014-06-26       Impact factor: 23.059

6.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

Authors:  Christina Ha; Thomas A Ullman; Corey A Siegel; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

7.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

8.  Role of disease risk scores in comparative effectiveness research with emerging therapies.

Authors:  Robert J Glynn; Joshua J Gagne; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-05       Impact factor: 2.890

9.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

10.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

Authors:  Brian G Feagan; John W D McDonald; Remo Panaccione; Robert A Enns; Charles N Bernstein; Terry P Ponich; Raymond Bourdages; Donald G Macintosh; Chrystian Dallaire; Albert Cohen; Richard N Fedorak; Pierre Paré; Alain Bitton; Fred Saibil; Frank Anderson; Allan Donner; Cindy J Wong; Guangyong Zou; Margaret K Vandervoort; Marybeth Hopkins; Gordon R Greenberg
Journal:  Gastroenterology       Date:  2013-11-21       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.